SCHEDULE: RTW Investments Holds 4.8% Stake in Spyre Therapeutics

RTW Investments, LP and Roderick Wong have disclosed a beneficial ownership of 4,251,996 shares, representing 4.8% of Spyre Therapeutics, Inc.'s common stock.

Summary

• RTW Investments, LP, an investment adviser, and Roderick Wong, its Managing Partner and Chief Investment Officer, have filed a Schedule 13G, indicating their beneficial ownership of Spyre Therapeutics, Inc. common stock.
• The filing reports a total of 4,251,996 shares owned, which constitutes 4.8% of the outstanding common stock.
• This ownership level is based on 87,936,477 shares outstanding as of June 24, 2026, as per Spyre Therapeutics' Form S-3ASR filing.
• The reporting persons have shared voting and dispositive power over these shares.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not controlling stake by an investment firm, suggesting confidence without immediate takeover intentions.

Positives

• Significant investment by RTW Investments, LP, a known investment adviser, suggests confidence in Spyre Therapeutics' potential.
• The 4.8% stake indicates a substantial holding, which could lead to increased investor interest.

Negatives

• The filing does not contain any negative financial or operational information about Spyre Therapeutics itself, as it is a disclosure of ownership.
• The ownership is not controlling, meaning RTW Investments cannot unilaterally dictate company strategy.

Risks

• The primary risk is that RTW Investments could decide to sell its stake, potentially impacting the stock price.
• Future actions by RTW Investments, such as increasing or decreasing their stake, could introduce volatility.
• The filing does not detail specific risks related to Spyre Therapeutics' business operations or market position.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Spyre Therapeutics. The future outlook for the stock will depend on Spyre Therapeutics' business performance and RTW Investments' future investment decisions.

Management Comments

• The filing should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stakes held by investment firms like RTW Investments in biotechnology companies are common, reflecting active portfolio management and belief in the sector's growth potential. This filing indicates RTW's continued interest in Spyre Therapeutics.

Stakeholder Impact

• Shareholders: May view the significant stake as a positive signal of institutional confidence, but also remain aware of potential future selling pressure.
• Management: The current stake does not imply direct control, but significant institutional ownership can influence board decisions and strategic direction over time.

Next Steps

• Monitor future filings from RTW Investments for any changes in their stake.
• Observe Spyre Therapeutics' operational and clinical developments, which will influence the value of RTW's investment.

Key Dates

Keywords

Spyre Therapeutics, RTW Investments, Schedule 13G, Beneficial Ownership, Roderick Wong, Investment Adviser, Common Stock, Ownership Stake